Russian pharmaceutical company Pharmasyntez has outlined its plans to export its own insulin products to countries in the CIS, as well as several nations in the Middle East, North Africa, and Southeast Asia. Nikita Punia, the executive director of Pharmasyntez, shared this information during the Biotechmed forum while speaking with TASS.
"We plan to supply our insulin products to countries within the CIS, as well as nations within the ASEAN (Association of Southeast Asian Nations) and MENA (Middle East and North Africa) regions," he stated when responding to a relevant query.
In July, the company announced three varieties of recombinant human insulin known as Gensulin M30, Gensulin H, and Gensulin P. Subsequently, in September, Pharmasyntez-Nord initiated the distribution of the inaugural batch of insulin glargine, which marks the introduction of the initial long-acting recombinant analog insulin into civilian usage.
"Pharmasyntez is currently in discussions with numerous countries regarding the provision of insulin manufactured at the Pharmasyntez-Nord facility," mentioned Punia. He added that the plant has an annual production capacity exceeding 5 million units. It's projected that approximately half of these insulin will be allocated to the domestic market, with the remaining half slated for export.
In terms of the company's international presence, they have already established representative offices in Vietnam and Uzbekistan. Information regarding new Pharmasyntez representative offices will be announced later this year based on ongoing negotiations. The company is actively engaged in these discussions.
Pharmasyntez also plans to expand its production capacity. They are set to launch a new phase of the East-Pharm plant in Ussuriysk in the summer of 2024 and the third phase of the Pharmasyntez-Nord plant in St. Petersburg in 2026. Furthermore, Pharmasyntez is making a substantial investment of 20 billion rubles in production within the Kaluga region.
About the company
Pharmasyntez Group is one of Russia's leading manufacturers of essential pharmaceuticals. The company's product range encompasses critical therapeutic areas, including treatments for tuberculosis, HIV, oncology, diabetes, and hepatitis. Their portfolio consists of over 300 drug products and more than 60 pharmaceutical substances. Over 80% of the medications they produce are listed as vital and essential drugs. Pharmasintez operates five production facilities located in Irkutsk, Ussuriysk, St. Petersburg, Bratsk, and Tyumen.
GSV "Russia - Islamic World"
Photo: wirestock/Freepik
Based on materials from TASS